The Schinus terebinthifolius Raddi is a native plant of South America popularly known in Brazil as aroeira. It is a medium-sized plant, which demonstrates a high adaptive potential in various environments, besides hav...The Schinus terebinthifolius Raddi is a native plant of South America popularly known in Brazil as aroeira. It is a medium-sized plant, which demonstrates a high adaptive potential in various environments, besides having various medicinal properties such as anti-inflammatory and antidiarrheal. Bacterial susceptibility tests were carried out and the minimal inhibitory concentration (MIC) was obtained. The results were interpreted based on the conventionally microbiological protocols and data from the CLSI. For the microbiological tests, microorganisms obtained from the American Type Culture Collection (ATCC), specifically, (Pseudomonas aeruginosa, Staphylococcus aureus and Encherichia coli) were used. Of the tested bacterial strains, only the Staphylococcus aureus 6538 presented susceptibility to the aroeira’s hydroalcoholic extract, forming zones of inhibition of 8.0 mm of diameter up to the MIC of 35.3 mg/mL, while the other tested strains showed to be resistant in all the concentrations of hydroalcoholic extract of the Schinus terebinthifolius Raddi bark. Our aim is to analyze the “in vitro” antibacterial potential of the 70% hydroalcoholic extract of the Schinus terebinthifolius Raddi.展开更多
Human immunodeficiency virus type 1 (HIV-1) is the causative agent of acquired immunodeficiency disease syndrome (AIDS).After over 26 years of efforts,there is still not a therapeutic cure or an effective vaccine agai...Human immunodeficiency virus type 1 (HIV-1) is the causative agent of acquired immunodeficiency disease syndrome (AIDS).After over 26 years of efforts,there is still not a therapeutic cure or an effective vaccine against HIV/AIDS.The clinical management of HIV-1 infected people largely relies on antiretroviral therapy (ART).Although highly active antiretroviral therapy (HAART) has provided an effective way to treat AIDS patients,the huge burden of ART in developing countries,together with the increasing incidence of drug resistant viruses among treated people,calls for continuous efforts for the development of anti-HIV-1 drugs.Currently,four classes of over 30 licensed antiretrovirals (ARVs) and combination regimens of these ARVs are in use clinically including:reverse transcriptase inhibitors (RTIs) (e.g.nucleoside reverse transcriptase inhibitors,NRTIs;and non-nucleoside reverse transcriptase inhibitors,NNRTIs),protease inhibitors (PIs),integrase inhibitors and entry inhibitors (e.g.fusion inhibitors and CCR5 antagonists).Here,we intend to provide updated information of currently available antiretroviral drugs for ART to promote the development of novel anti-HIV-1 drugs.展开更多
文摘The Schinus terebinthifolius Raddi is a native plant of South America popularly known in Brazil as aroeira. It is a medium-sized plant, which demonstrates a high adaptive potential in various environments, besides having various medicinal properties such as anti-inflammatory and antidiarrheal. Bacterial susceptibility tests were carried out and the minimal inhibitory concentration (MIC) was obtained. The results were interpreted based on the conventionally microbiological protocols and data from the CLSI. For the microbiological tests, microorganisms obtained from the American Type Culture Collection (ATCC), specifically, (Pseudomonas aeruginosa, Staphylococcus aureus and Encherichia coli) were used. Of the tested bacterial strains, only the Staphylococcus aureus 6538 presented susceptibility to the aroeira’s hydroalcoholic extract, forming zones of inhibition of 8.0 mm of diameter up to the MIC of 35.3 mg/mL, while the other tested strains showed to be resistant in all the concentrations of hydroalcoholic extract of the Schinus terebinthifolius Raddi bark. Our aim is to analyze the “in vitro” antibacterial potential of the 70% hydroalcoholic extract of the Schinus terebinthifolius Raddi.
基金supported by HKU-UDF,HKSARG FHB/RFCID09080772the National Basic Research Program of China(2008ZX10001-011 and 2008ZX10001-015)
文摘Human immunodeficiency virus type 1 (HIV-1) is the causative agent of acquired immunodeficiency disease syndrome (AIDS).After over 26 years of efforts,there is still not a therapeutic cure or an effective vaccine against HIV/AIDS.The clinical management of HIV-1 infected people largely relies on antiretroviral therapy (ART).Although highly active antiretroviral therapy (HAART) has provided an effective way to treat AIDS patients,the huge burden of ART in developing countries,together with the increasing incidence of drug resistant viruses among treated people,calls for continuous efforts for the development of anti-HIV-1 drugs.Currently,four classes of over 30 licensed antiretrovirals (ARVs) and combination regimens of these ARVs are in use clinically including:reverse transcriptase inhibitors (RTIs) (e.g.nucleoside reverse transcriptase inhibitors,NRTIs;and non-nucleoside reverse transcriptase inhibitors,NNRTIs),protease inhibitors (PIs),integrase inhibitors and entry inhibitors (e.g.fusion inhibitors and CCR5 antagonists).Here,we intend to provide updated information of currently available antiretroviral drugs for ART to promote the development of novel anti-HIV-1 drugs.
